24/7 Patient Assistance: 760-405-8205

John S. Link, MD

Medical Oncologist

Write a review
Doctor's profile photo

Request a call back

Conditions Treated Asbestosis Laryngeal Cancer Pericardial Mesothelioma Peritoneal Mesothelioma Pleural Mesothelioma

  • Bio & Insurance Information

    Dr. Link graduated from the Keck School of Medicine of USC and completed his residency program at the University of Southern California. He is specialized in Medical Oncology and board certified in Internal Medicine and Oncology. Dr. Link has been in practice for more than 20 years and is affiliated with the Children's Hospital of Orange County and St. Joseph Hospital of Orange. During his career, he has also contributed to several clinical research publications.

  • Education & Training


    Keck School of Medicine of USC

    Medical School


    University of Southern California - LAC+USC Medical Center


  • Board Certifications

    American Board of Internal Medicine

    American Board of Internal Medicine - Oncology

  • Hospital & Practice

    Children's Hospital of Orange County

    Languages: English/Spanish

    (714) 997-3000

    1201 W La Veta Ave

    Orange, California 92868

    Read More

    St Joseph Hospital Of Orange

    Languages: English/Spanish

    (714) 633-9111

    1100 W Stewart Dr

    Orange, California 92868

    Read More
  • Publications & Memberships

    Dr. John S. Link has contributed to 3 publications.

    A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1-4 hepatitis C virus.

    Lawitz, E.,Freilich, B.,Link, J.,German, P.,Mo, H.,Han, L.,Brainard, D. M.,McNally, J.,Marbury, T.,Rodriguez-Torres, M.; J. Viral Hepat.. 2015 Jul 18.

    See more >>

    Project Connect Online: Randomized Trial of an Internet-Based Program to Chronicle the Cancer Experience and Facilitate Communication.

    Stanton, A. L.,Thompson, E. H.,Crespi, C. M.,Link, J. S.,Waisman, J. R.; J. Clin. Oncol.. 2013 Sep 20.

    See more >>

    The HCV Non-Nucleoside Inhibitor Tegobuvir Utilizes a Novel Mechanism of Action to Inhibit NS5B Polymerase Function.

    Hebner, C. M., Han, B., Brendza, K. M., Nash, M., Sulfab, M., Tian, Y., Hung, M., Fung, W., Vivian, R. W., Trenkle, J., Taylor, J., Bjornson, K., Bondy, S., Liu, X., L...; PLoS ONE. 2012.

    See more >>